Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- JPMA to Watch Regulators’ Moves to Decide Its Action on Kaketsuken
December 18, 2015
- JPMA Says Re-Pricing of Huge-Seller Drugs Unreasonable, Preparing Statement
December 18, 2015
- Lilly’s Jonsson to Become Japan Chief of PhRMA
December 18, 2015
- PhRMA Sounds Alarm on “Huge Seller” Re-Pricing, Possible Decline in Japan Investment
December 14, 2015
- JGA Chief Opposes 50% First Generic Pricing for Non-Oral Drugs with Adoair, Symbicort Generics in Mind
December 11, 2015
- JPMA Sets to Respond Harshly to Kaketsuken Cover-Up: Chief
December 8, 2015
- JPMA Requests on Price Revisions, Tax Seem to Have Sunk in for Politicians: Exec
November 20, 2015
- 6 Insurers Tender Request for FY2016 Reform, Say Healthcare Costs Must Be Cut with HTA, Generics
November 19, 2015
- Industry Wants OTC Tax Break and No Annual Price Cuts, Groups Tell LDP
November 19, 2015
- Pharma Leaders Rev Up Lobbying Campaigns ahead of Year-End Budget, Tax Debates
November 18, 2015
- FPMAJ Gives Up on Crafting Rules for Disclosing Joint Generic Developers
October 27, 2015
- Reflect Industry Opinions in Pilot Introduction of Cost-Effective Assessments: JPMA
October 27, 2015
- JPMA Says Its Demands Generally Accepted in TPP, No Impact Expected on Japan Market
October 23, 2015
- EFPIA Poised to Lobby Japan on Vaccine Regulations in EPA Talks
October 22, 2015
- AMDJ to Draw Up Voluntary Rules for Managing Big Data in Field of Healthcare
October 14, 2015
- ACCJ Applauds Conclusion of TPP Talks
October 8, 2015
- EFPIA Vice President Has High Hopes for Japan’s Innovation
October 7, 2015
- EFPIA Director General Welcomes Broad Deal Reached on TPP
October 7, 2015
- JPMA President Congratulates Nobel Laureate Omura
October 7, 2015
- Drug Pricing Tomorrow: Full Interview with JMA Vice President Nakagawa
October 5, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…